Cotter Thomas G, Ayoub Fares, King Andrea C, Reddy Kapuluru Gautham, Charlton Michael
Division of Gastroenterology & Hepatology, Center for Liver Diseases, The University of Chicago Medicine, Chicago, IL.
Department of Psychiatry & Behavioral Neuroscience, University of Chicago, Chicago, IL.
Transplant Direct. 2020 Sep 17;6(10):e603. doi: 10.1097/TXD.0000000000001054. eCollection 2020 Oct.
The prevalence of alcohol use disorder (AUD) and alcohol-associated liver disease is increasing in the United States. Efficacious AUD pharmacotherapies, while available, are, for protean reasons, underutilized. Hepatology providers may be in a position to bridge the pharmacotherapeutic gap between availability and utilization of AUD pharmacotherapies. Our aim was to ascertain the current practice, knowledge and attitudes of hepatology physicians in the United States, and identify opportunities on how to increase AUD medication prescribing.
A web-based survey, developed by an expert panel, was administered to hepatology physicians working at all transplant centers in the United States.
The survey response rate was 131/658 (20%). There was significant support (two-thirds of respondents) for hepatology providers prescribing AUD medications; however, only 1 in 4 was comfortable prescribing these medications. The majority felt additional education is needed to prescribe AUD medications. The practice of hepatology providers prescribing AUD medications is common, with >50% of respondents having done so. Baclofen was the most popular medication prescribed. Hepatology providers perceived suboptimal ancillary addiction services. Although AUD prescribers had higher rates of AUD pharmacotherapy knowledge compared with nonprescribers, approximately 50% still had inadequate knowledge.
AUD medication prescribing is a common practice among hepatology providers who appear eager to increase this practice through more education as they attempt to bridge the pharmacotherapeutic gap. This informative survey provides guidance for professional societies on how best to disseminate the requisite education required to optimize the care of patients with AUD.
在美国，酒精使用障碍（AUD）和酒精相关肝病的患病率正在上升。虽然有有效的AUD药物治疗方法，但由于多种原因，这些方法未得到充分利用。肝病学提供者可能有能力弥合AUD药物治疗方法在可得性和利用率之间的药物治疗差距。我们的目的是确定美国肝病科医生目前的实践、知识和态度，并找出增加AUD药物处方的机会。
由一个专家小组开发的基于网络的调查问卷被发放给在美国所有移植中心工作的肝病科医生。
调查回复率为131/658（20%）。对于肝病学提供者开具AUD药物有显著支持（三分之二的受访者）；然而，只有四分之一的人对开具这些药物感到放心。大多数人认为开具AUD药物需要更多教育。肝病学提供者开具AUD药物的做法很常见，超过50%的受访者这样做过。巴氯芬是最常开具的药物。肝病学提供者认为辅助成瘾服务不理想。虽然与不开具AUD药物的人相比，开具AUD药物的人对AUD药物治疗知识的掌握率更高，但仍约有50%的人知识不足。
在肝病学提供者中，开具AUD药物是一种常见做法，他们似乎渴望通过更多教育来增加这种做法，因为他们试图弥合药物治疗差距。这项信息丰富的调查为专业协会提供了指导，说明如何最好地传播优化AUD患者护理所需的必要教育。
